Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW: Reproxalap in dry eye disease
NCT03879863Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of reproxalap in dry eye disease (DED) (4 arms), sponsored by Aldeyra Therapeutics. Primary endpoints: Subject-reported Ocular Dryness Score at 12 weeks and Fluorescein Nasal Region Score at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
reproxalap
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03879863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879863.